Mr. Stephen Van Deventer reports

PREVECEUTICAL MEDICAL AND BIOGENE THERAPEUTICS ANNOUNCE CLOSING OF PLAN OF ARRANGEMENT

Further to the news releases of Sept. 4, 2025, Sept. 19, 2025, Oct. 10, 2025, Oct. 20, 2025, and Nov. 20, 2025, the previously announced plan of arrangement involving the spinoff of 12 million shares of BioGene Therapeutics Inc. from Preveceutical Medical Inc. became effective Nov. 25, 2025.

The arrangement

The arrangement was approved by the shareholders of Preveceutical's common shares at its annual general and special meeting held on Oct. 10, 2025, and by the Supreme Court of British Columbia in its final order dated Oct. 17, 2025.

Pursuant to the arrangement agreement, Preveceutical conducted a share capital reorganization whereby the existing common shares of Preveceutical were renamed and redesignated as Class A common shares and a new class of voting common shares was created. Each Preveceutical Class A share was exchanged for one new Preveceutical share and 0.02 common share of BioGene. The shareholders at the close of business on Nov. 25, 2025, received one new Preveceutical share and 0.02 BioGene spinout share in exchange for each Preveceutical share that was held by such shareholder. Preveceutical shareholders now own shares in two companies: BioGene, which will focus on the development of the dual gene therapy program, and Preveceutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.